Characterization of drug-resistant influenza A(H7N9) variants isolated from an oseltamivir-treated patient in Taiwan
- PMID: 25124927
- PMCID: PMC6943751
- DOI: 10.1093/infdis/jiu447
Characterization of drug-resistant influenza A(H7N9) variants isolated from an oseltamivir-treated patient in Taiwan
Abstract
Background: Patients contracting influenza A(H7N9) infection often developed severe disease causing respiratory failure. Neuraminidase (NA) inhibitors (NAIs) are the primary option for treatment, but information on drug-resistance markers for influenza A(H7N9) is limited.
Methods: Four NA variants of A/Taiwan/1/2013(H7N9) virus containing a single substitution (NA-E119V, NA-I222K, NA-I222R, or NA-R292K) recovered from an oseltamivir-treated patient were tested for NAI susceptibility in vitro; their replicative fitness was evaluated in cell culture, mice, and ferrets.
Results: NA-R292K led to highly reduced inhibition by oseltamivir and peramivir, while NA-E119V, NA-I222K, and NA-I222R caused reduced inhibition by oseltamivir. Mice infected with any virus showed severe clinical signs with high mortality rates. NA-I222K virus was the most virulent in mice, whereas virus lacking NA change (NA-WT) and NA-R292K virus seemed the least virulent. Sequence analysis suggests that PB2-S714N increased virulence of NA-I222K virus in mice; NS1-K126R, alone or in combination with PB2-V227M, produced contrasting effects in NA-WT and NA-R292K viruses. In ferrets, all viruses replicated to high titers in the upper respiratory tract but produced only mild illness. NA-R292K virus, showed reduced replicative fitness in this animal model.
Conclusions: Our data highlight challenges in assessment of the replicative fitness of H7N9 NA variants that emerged in NAI-treated patients.
Keywords: E119V; H7N9; I222K; I222R; R292K; ferrets; influenza virus; mice; oseltamivir; peramivir.
© The Author 2014. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.
Conflict of interest statement
All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
Figures



Similar articles
-
Neuraminidase Mutations Conferring Resistance to Oseltamivir in Influenza A(H7N9) Viruses.J Virol. 2015 May;89(10):5419-26. doi: 10.1128/JVI.03513-14. Epub 2015 Mar 4. J Virol. 2015. PMID: 25740997 Free PMC article.
-
Resistance to neuraminidase inhibitors conferred by an R292K mutation in a human influenza virus H7N9 isolate can be masked by a mixed R/K viral population.mBio. 2013 Jul 16;4(4):e00396-13. doi: 10.1128/mBio.00396-13. mBio. 2013. PMID: 23860768 Free PMC article.
-
Substitution of I222L-E119V in neuraminidase from highly pathogenic avian influenza H7N9 virus exhibited synergistic resistance effect to oseltamivir in mice.Sci Rep. 2021 Aug 11;11(1):16293. doi: 10.1038/s41598-021-95771-4. Sci Rep. 2021. PMID: 34381119 Free PMC article.
-
R229I substitution from oseltamivir induction in HA1 region significantly increased the fitness of a H7N9 virus bearing NA 292K.Emerg Microbes Infect. 2024 Dec;13(1):2373314. doi: 10.1080/22221751.2024.2373314. Epub 2024 Jul 16. Emerg Microbes Infect. 2024. PMID: 38922326 Free PMC article.
-
The R292K mutation that confers resistance to neuraminidase inhibitors leads to competitive fitness loss of A/Shanghai/1/2013 (H7N9) influenza virus in ferrets.J Infect Dis. 2014 Dec 15;210(12):1900-8. doi: 10.1093/infdis/jiu353. Epub 2014 Jun 20. J Infect Dis. 2014. PMID: 24951824 Free PMC article.
Cited by
-
Antiviral Activity of 3D, a Butene Lactone Derivative Against Influenza A Virus In Vitro and In Vivo.Viruses. 2021 Feb 11;13(2):278. doi: 10.3390/v13020278. Viruses. 2021. PMID: 33670217 Free PMC article.
-
Orally Efficacious Broad-Spectrum Ribonucleoside Analog Inhibitor of Influenza and Respiratory Syncytial Viruses.Antimicrob Agents Chemother. 2018 Jul 27;62(8):e00766-18. doi: 10.1128/AAC.00766-18. Print 2018 Aug. Antimicrob Agents Chemother. 2018. PMID: 29891600 Free PMC article.
-
Efficacy of oseltamivir-peramivir combination therapy compared to oseltamivir monotherapy for Influenza A (H7N9) infection: a retrospective study.BMC Infect Dis. 2016 Feb 10;16:76. doi: 10.1186/s12879-016-1383-8. BMC Infect Dis. 2016. PMID: 26864456 Free PMC article.
-
Identification of a novel compound targeting the nuclear export of influenza A virus nucleoprotein.J Cell Mol Med. 2018 Mar;22(3):1826-1839. doi: 10.1111/jcmm.13467. Epub 2017 Nov 30. J Cell Mol Med. 2018. PMID: 29193684 Free PMC article.
-
Novel Avian Influenza A Virus Infections of Humans.Infect Dis Clin North Am. 2019 Dec;33(4):907-932. doi: 10.1016/j.idc.2019.07.003. Infect Dis Clin North Am. 2019. PMID: 31668198 Free PMC article. Review.
References
-
- WHO. Number of confirmed human cases of avian influenza A(H7N9) reported to WHO. http://www.who.int/influenza/human_animal_interface/influenza_h7n9/14_Re.... Accessed 11 March 2014.
-
- WHO. Human infection with avian influenza A(H7N9) virus—update 2014. http://www.who.int/csr/don/archive/year/2014/en/index.html. Accessed 11 March 2014.
-
- Gao R, Cao B, Hu Y, et al. Human infection with a novel avian-origin influenza A (H7N9) virus. N Engl J Med 2013; 368:1888–97. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical